CYT-500-Lu-177

N/A

Report date: 2025/10/20 14:43:42

Base Information

Drug NameCYT-500-Lu-177

Drug Alias NameAnti-PSMA-meO-DOTA-177Lu7E11-C5.3-meO- DOTA-177Lu177LuCYT500CYT-500-Lu-177177Lu-CYT-500 +[7]

ClassificationRadiation-emitting products > Nuclides > Lutetium > 177LuRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug Conjugates +[4]

Mechanisms of ActionIonising radiation emittersAnti-PSMA

TargetsProstate-Specific Membrane Antigen

Therapy Area/IndicationsProstatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesCytogen Corp

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesCytogen Corp

Active IndicationsN/A

Inactive IndicationsProstatic Neoplasms

Other Information

ATC CodeN/A